Chemotherapy Induced Anemia - Pipeline Review, Q1 2011

Published : March 2011
No. of Pages : 39

Price:

Summary

Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, Q1 2011', provides an overview of the Chemotherapy Induced Anemia therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. 'Chemotherapy Induced Anemia - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Chemotherapy Induced Anemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chemotherapy Induced Anemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chemotherapy Induced Anemia 7
Chemotherapy Induced Anemia Therapeutics under Development by Companies 9
Chemotherapy Induced Anemia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Chemotherapy Induced Anemia Therapeutics - Products under Development by Companies 15
Chemotherapy Induced Anemia Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 17
Kyowa Hakko Kirin Co., Ltd. 17
3SBio Inc. 17
ProMetic Life Sciences Inc. 18
Affymax, Inc. 18
Sinobiomed, Inc. 19
Acceleron Pharma, Inc. 19
AplaGen GmbH 20
Orcrist Bio Inc. 20
Chemotherapy Induced Anemia - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 26
Late Stage Drug Profiles – Companies 29
NESP - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Late Stage Drug Profiles – Universities/Institutes 30
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Chemotherapy Induced Anemia - Featured News 31
Jun 18, 2010: Chugai Pharmaceutical Co., Ltd Got Recombinant Human Erythropoietin, “EPOGIN Subcutaneous Injection Syringe 24000,” Approved In Japan 31
Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 31
Mar 02, 2010: Lipoxen Initiates Phase II Trial Of ErepoXen In India 32
Dec 01, 2009: Acceleron Pharma To Present Clinical Trial Results Of ACE-011 At The 51st Annual Meeting Of The American Society Of Hematology 33
Jul 28, 2009: Acceleron and Celgene Initiate Phase II Study of ACE-011 to Treat Chemotherapy-Induced Anemia 33
May 06, 2009: Lipoxen Plc Announces Positive Phase I Clinical Trial Results For ErepoXen 34
Jun 16, 2008: Lipoxen Receives Approval To Conduct Second Phase I Trial Of Its Long-Acting Erythropoietin (EPO), ErepoXen, In Canada 35
Apr 21, 2008: Lipoxen Announces Positive Phase I Results With Its Long Acting EPO Product Candidate, ErepoXen 36
Mar 12, 2008: Non-Approvable Letter Received From The FDA 36
Feb 13, 2008: Lipoxen Announces Initiation Of Phase I Trials Of It Long-Acting Erythropoietin (EPO), ErepoXen 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 39
Contact Us 39
Disclaimer 39

Chemotherapy Induced Anemia - Pipeline Review, Q1 2011

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: